慢性病防治专栏

祛湿活血方调控AMPK/SREBP1c信号通路对HepG2脂肪肝细胞生长的影响

  • 谭伟强 ,
  • 刘丽 ,
  • 刘旭东 ,
  • 魏业煌 ,
  • 龚晓倩 ,
  • 王蓉蓉
展开
  • 1.广西中医药大学研究生院 (广西 南宁 530004 )
    2.广西中医药大学附属瑞康医院肝病科 (广西 南宁 530004 )

收稿日期: 2025-10-10

  网络出版日期: 2026-02-09

基金资助

国家自然科学基金项目(82560866);国家自然科学基金项目(82160837);全国中医临床优秀人才研修项目(国中医药人教函[2022]1号);广西研究生教育创新计划项目(YCBZ2025189);2022年广西(青年)岐黄学者培养项目

The effect of the Qushi Huoxue decoction on the AMPK/SREBP1c signaling pathway in free fatty acid-induced HepG2 cells

  • Weiqiang TAN ,
  • Li LIU ,
  • Xudong LIU ,
  • Yehuang WEI ,
  • Xiaoqian GONG ,
  • Rongrong WANG
Expand
  • 1.Graduate School of Guangxi University of Chinese Medicine,Nanning 530004,Guangxi,China
    2.Department of Hepatology,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530004,Guangxi,China

Received date: 2025-10-10

  Online published: 2026-02-09

摘要

目的 探究祛湿活血方对游离脂肪酸(FFA)诱导的HepG2细胞的作用及机制。 方法 采用体外细胞实验,利用CCK8法测定不同浓度祛湿活血方对HepG2细胞活性的影响以选定适宜浓度进行后续实验。随后使用250 μmol/L棕榈酸钠溶液联合500 μmol/L油酸钠的游离脂肪酸处理24 h诱导建立脂肪肝细胞模型,并给予不同浓度祛湿活血方含药血清及AMPK抑制剂对HepG2细胞进行24 h干预。通过油红O染色法和脂质荧光染色法观察细胞内脂滴积聚情况,采用GPO-PAP酶法检测细胞内总胆固醇(TC)和甘油三酯(TG)含量变化,TBA法检测和羟胺法分别检测丙二醛(MDA)和超氧化物歧化酶(SOD)的含量,ELISA检测肿瘤坏死因子-α(TNF-α)和白细胞介素1β(IL-1β)的含量,进一步运用qRT-PCR、Western blot和免疫荧光染色技术检测细胞内脂质代谢相关基因及蛋白的表达。 结果 祛湿活血方可显著改善FFA诱导的HepG2细胞脂质沉积,氧化应激及炎症反应,显著降低细胞中TC、TG、MDA、TNF-α、IL-1β的含量和提高SOD活性(P < 0.01),提高AMPK,降低SREBP1c、FASN、ACC1和SCD1的mRNA表达水平(P < 0.05),以及增加p-AMPK/AMPK,降低SREBP1c、FASN、ACC1和SCD1的蛋白表达(P<0.05)。 结论 祛湿活血方能够显著改善MASLD细胞模型的脂质代谢,并减轻氧化应激及炎症反应,其机制可能与激活AMPK/SREBP1c信号通路有关。

本文引用格式

谭伟强 , 刘丽 , 刘旭东 , 魏业煌 , 龚晓倩 , 王蓉蓉 . 祛湿活血方调控AMPK/SREBP1c信号通路对HepG2脂肪肝细胞生长的影响[J]. 实用医学杂志, 2026 , 42(3) : 406 -415 . DOI: 10.3969/j.issn.1006-5725.2026.03.007

Abstract

Objective To investigate the effect of Qushi Huoxue decoction (QSHXF) on free fatty acid (FFA)-induced HepG2 cells and its underlying mechanism. Methods In vitro cell experiments were conducted. First, the CCK-8 assay was used to determine the effects of different concentrations of QSHXF on HepG2 cells viability to select appropriate concentrations for subsequent experiments. A fatty liver cell model was then established by treating HepG2 cells with a mixture of 250 μmol/L sodium palmitate and 500 μmol/L sodium oleate for 24 h, followed by intervention with different concentrations of QSHXF-containing serum and AMPK inhibitor for another 24 h. Intracellular lipid droplet accumulation was observed using Oil Red O staining and lipid fluorescence staining. The levels of total cholesterol (TC) and triglycerides (TG) were measured using the GPO-PAP enzymatic method. The TBA method and hydroxylamine method were used to detect malondialdehyde (MDA) and superoxide dismutase (SOD), respectively, while ELISA was used to detect tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β). Furthermore, qRT-PCR, Western blot, and immunofluorescence staining were performed to detect the expression of lipid metabolism-related genes and proteins. Results QSHXF significantly improved the lipid deposition, oxidative stress and inflammatory response of FFA-induced HepG2 cells, markedly reduce the content of TC, TG, MDA, TNF-α and IL-1β in cells and increase the activity of SOD (P < 0.01). Meanwhile, it increased the mRNA expression of AMPK and the protein ratio of p-AMPK/AMPK, while decreasing the mRNA and protein levels of SREBP1c, FASN, ACC1, and SCD1 (all P < 0.05). Conclusion QSHXF significantly improved lipid metabolism and alleviated oxidative stress and inflammation in the MASLD cell model, and its mechanism may be associated with the activation of the AMPK/SREBP1c signaling pathway.

参考文献

[1] STEFAN N, SCHICK F, BIRKENFELD A L, et al. The role of hepatokines in NAFLD[J]. Cell Metab, 2023, 35(2): 236-252. doi: 10.1016/j.cmet.2023.01.006 .
[2] 范建高, 杨蕊旭. 代谢相关脂肪性肝病的中西医结合治疗现状与展望[J]. 中国中西医结合消化杂志, 2025, 33(4): 402-405. doi: 10.3969/j.issn.1671-038X.2025.04.06 .
[3] 梁红,陈洁.代谢相关脂肪性肝病与双相情感障碍的共享遗传研究[J].新医学,2025,56(11):1073-1082. doi: 10.12464/j.issn.0253-9802.2025-0233 .
[4] LAZARUS J V, MARK H E, VILLOTA-RIVAS M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?[J]. J Hepatol, 2022, 76(4): 771-780. doi: 10.1016/j.jhep. 2021. 10.025 .
[5] POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22(1): 63. doi: 10.1186/s12902-022-00980-1 .
[6] KHAZNADAR F, KHAZNADAR O, PETROVIC A, et al. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development[J]. Curr Issues Mol Biol, 2024, 46(7): 6300-6314. doi: 10.3390/cimb46070376 .
[7] 李军祥, 白宇宁, 王允亮, 等. 非酒精性脂肪性肝病中西医结合诊疗专家共识(2025年)[J].中国中西医结合消化杂志, 2025, 33(4): 339-350. doi: 10.3969/j.issn.1671-038X.2025.04.01 .
[8] 徐新杰, 吴银凤, 吕萍, 等. 刘旭东教授治疗非酒精性脂肪肝经验总结[J]. 广西中医药, 2018, 41(1): 38-40. doi: 10.3969/j.issn.1003-0719.2018.01.017 .
[9] 刘旭东, 涂燕云, 张红星. 祛湿活血中药治疗非酒精性脂肪肝40例[J]. 陕西中医, 2013, 34(1): 16-8. doi: 10.3969/j.issn. 1000-7369.2013.01.008 .
[10] 沈震, 费新应, 刘旭东. 祛湿活血方对慢性乙型肝炎合并非酒精性脂肪性肝病患者抗病毒疗效的影响[J]. 湖北中医杂志, 2015, 37(8): 38-39.
[11] 吴铁雄, 刘旭东, 冉小柯, 等. 基于经典焦亡通路探讨祛湿活血方治疗NASH小鼠的作用机制[J]. 时珍国医国药, 2024, 35(4): 769-773. doi: 10.3969/j.issn.1008-0805.2024.04.01 .
[12] 谭伟强, 冉小柯, 潘兆权, 等. 基于网络药理学及实验验证探讨祛湿活血方治疗非酒精性脂肪性肝病的作用机制[J]. 中国药理学通报, 2025, 41(9): 1761-1768. doi: 10.12360/CPB202411055 .
[13] NIE Y, MENG W, LIU D, et al. Exosomes derived from apical papilla stem cells improve NASH by regulating fatty acid metabolism and reducing inflammation[J]. Mol Med, 2024, 30(1): 186. doi: 10.1186/s10020-024-00945-1 .
[14] 刘彤, 李善政, 周铖, 等. 芍药苷对棕榈酸诱导的HepG2细胞的保护作用及其机制[J]. 临床肝胆病杂志, 2025, 41(3): 499-505. doi: 10.12449/JCH250316 .
[15] LAN T, YU Y, ZHANG J, et al. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway[J]. Hepatology, 2021, 74(2): 686-703. doi: 10.1002/hep.31749 .
[16] LIU B, ZHANG J, SUN P, et al. Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice[J]. Biomolecules, 2019, 9 (9): 435. doi: 10.3390/biom9090435 .
[17] 谭明, 张慧, 任吉华, 等. 脂质代谢紊乱在非酒精性脂肪性肝病中的作用概述[J]. 胃肠病学和肝病学杂志, 2024, 33(8): 1082-1086. doi: 10.3969/j.issn.1006-5709.2024.08.025 .
[18] 孙鹏帅, 朱峰, 郑丽红, 等. AMP依赖的蛋白激酶调节脂质积累治疗非酒精性脂肪肝病的治疗研究进展[J]. 实用医学杂志, 2024, 40(6): 862-866. doi: 10.3969/j.issn.1006-5725. 2024. 06.022 .
[19] HUANG C, GAO X, SHI Y, et al. Inhibition of Hepatic AMPK Pathway Contributes to Free Fatty Acids-Induced Fatty Liver Disease in Laying Hen[J]. Metabolites, 2022, 12(9): 825. doi: 10.3390/metabo12090825 .
[20] 淡丽娟, 陈双兰, 王天媛, 等. 中医药调控AMPK信号通路防治非酒精性脂肪性肝病的研究进展[J/OL]. 中国实验方剂学杂志, 2025. doi: 10.13422/j.cnki.syfjx.20251538 .
[21] 徐新杰, 吴银凤, 吕萍, 等. 刘旭东教授治疗非酒精性脂肪肝经验总结[J]. 广西中医药, 2018, 41(1): 38-40. doi: 10.3969/j.issn.1003-0719.2018.01.017 .
[22] 赵东波, 王昊, 黄樱, 等. 虎杖苷相关AMPK信号通路对非酒精性脂肪肝病小鼠肝脏脂质沉积的作用研究[J]. 国际医药卫生导报, 2022, 28(3): 329-332. doi: 10.3760/cma.j.issn.1007-1245.2022.03.008 .
[23] 王希文, 贺琼, 杜凡, 等. 大黄酸通过Sirt1/AMPK信号通路对非酒精性脂肪性肝病小鼠肝功能及肝细胞脂代谢的影响[J]. 中西医结合肝病杂志, 2023, 33(11): 1000-1006. doi: 10.3969/j.issn.1005-0264.2023.011.009 .
[24] ZHU J, GUO J, LIU Z, et al. Salvianolic acid A attenuates non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1 pathway[J]. Chem Biol Interact, 2024, 400: 111162. doi: 10.1016/j.cbi.2024.111162 .
[25] 洪祝平, 张建华, 史月姣, 等. 基于非酒精性脂肪肝细胞模型的荷叶水提物降脂作用机制研究[J]. 现代中药研究与实践, 2024, 38(2): 41-47. doi: 10.13728/j.1673-6427.2024.02.008 .
[26] GNONI A, DI CHIARA STANCA B, GIANNOTTI L, et al. Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis[J]. Int J Mol Sci, 2022, 23(3): 1044. doi: 10.3390/ijms23031044 .
文章导航

/